The purpose of this study is to evaluate the safety of administering a combination vaccine
(DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration
of a HepB vaccine at birth and the same combination vaccine at 2, 4, and 6 months of age.
Additionally, researchers will assess the body's antibody response (proteins produced by the
body's immune system that help fight infections) following each vaccine dose. The study will
enroll 5 healthy newborns, ages 0-5 days. Participants will be involved in study related
procedures for up to 288 days, including blood sample collection and 5 study visits.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)